Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis
Clinical Scorecard: Comparative Analysis of Surgical Resection and Biopsy for Managing Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Primary Central Nervous System Lymphoma (PCNSL)
Key Mechanisms
Aggressive diffuse large B-cell lymphoma primarily affecting CNS; responds to high-dose methotrexate chemotherapy; diagnosis via MRI and biopsy
Target Population
Predominantly elderly patients and those with compromised immune systems
Care Setting
Neuro-oncology and neurosurgical care settings involving diagnostic imaging, biopsy, chemotherapy, and potential surgical intervention
Key Highlights
PCNSL accounts for ~6.7% of CNS tumors with poor prognosis and 5-year survival ~28%.
Standard diagnosis involves MRI followed by biopsy for histopathological confirmation.
Role of surgical resection remains unclear; meta-analysis compares survival outcomes of resection versus biopsy.
Guideline-Based Recommendations
Diagnosis
Use MRI as initial diagnostic imaging for suspected PCNSL.
Confirm diagnosis with histopathological biopsy before treatment initiation.
Management
First-line treatment is high-dose methotrexate-based chemotherapy.
Surgical resection traditionally contraindicated except for large lesions causing increased intracranial pressure or herniation symptoms.
Consider surgical resection on a case-by-case basis given emerging evidence of potential benefit.
Monitoring & Follow-up
Monitor for progression-free survival and overall survival post-treatment.
Assess for neurological symptoms and complications following biopsy or resection.
Risks
Surgical resection may carry risks of postoperative complications; benefits versus risks remain uncertain.
High risk of primary refractory disease and relapse despite chemotherapy.
Patient & Prescribing Data
Patients diagnosed with PCNSL undergoing either surgical resection or biopsy
Approximately one-third of patients are refractory to first-line chemotherapy; surgical resection may improve survival in select cases but evidence is mixed.
Clinical Best Practices
Perform thorough eligibility assessment before deciding between biopsy and resection.
Use multidisciplinary consensus to tailor treatment approach based on lesion size, location, and patient condition.
Apply high-dose methotrexate chemotherapy promptly after diagnosis.
Consider surgical intervention primarily for symptomatic mass effect or when biopsy is insufficient.
A Keck Medicine of USC neurointerventionalist discusses how a minimally invasive, endovascularly implantable cerebrospinal fluid shunt is the next-generation treatment for normal pressure hydrocephalus — and possibly more.
